Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

BACKGROUND: Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2–3 years. A subgroup of those patients with mCRPC presents with oligoprogressive disease, with a limited number of progressiv...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Berghen, Charlien, Joniau, Steven, Rans, Kato, Devos, Gaëtan, Poels, Kenneth, Slabbaert, Koen, Dumez, Herlinde, Albersen, Maarten, Goffin, Karolien, Haustermans, Karin, De Meerleer, Gert
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7245754/
https://ncbi.nlm.nih.gov/pubmed/32448171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-06853-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados